Nipro (NPRRF) Debt-to-Asset : 0.58 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Nipro Debt-to-Asset?

Nipro's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,419 Mil. Nipro's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3,045 Mil. Nipro's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $7,723 Mil. Nipro's debt to asset for the quarter that ended in Dec. 2023 was 0.58.

Nipro Debt-to-Asset Historical Data

The historical data trend for Nipro's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nipro Debt-to-Asset Chart

Nipro Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Asset

Get a 7-Day Free Trial

0.65

0.64

0.61

0.59

0.57

Nipro Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.59	0.58	0.58	0.58	0.57

Competitive Comparison of Nipro's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, Nipro's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nipro's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nipro's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Nipro's Debt-to-Asset falls into.

Nipro Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Nipro's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1304.284	+	2938.761)	/	7407.765
	=	0.57

Nipro's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1419.224	+	3045.454)	/	7722.513
	=	0.58

Nipro (OTCPK:NPRRF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Nipro Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Nipro's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nipro (NPRRF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nipro Corp (OTCPK:NPRRF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

8086:Japan

Address

3-9-3 Honjo-Nishi Kita-ku, Osaka, JPN, 531-8510

Website

http://www.nipro.co.jp

Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.

Nipro (NPRRF) Headlines

No Headlines